Left ventricular mass and volume with telmisartan, ramipril, or combination in patients with previous atherosclerotic events or with diabetes mellitus (from the ONgoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial [ONTARGET])

The American Journal of Cardiology
Brett R CowanONTARGET Investigators

Abstract

The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET) showed that the angiotensin receptor blocker telmisartan 80 mg was not inferior to the angiotensin-converting enzyme inhibitor ramipril 10 mg, and the combination no more effective than ramipril alone, in decreasing morbidity and mortality in patients with cardiovascular disease or high-risk diabetes. Although therapy targeting angiotensin II is known to decrease left ventricular (LV) mass and volume, the relative influence of angiotensin-converting enzyme inhibitor inhibitors and angiotensin receptor blocker, and their combination, on the heart remains unclear in this population. Magnetic resonance imaging was performed in 287 patients enrolled in ONTARGET, across 8 centers in 6 countries, at randomization and after 2-year treatment (90, 100, and 97 patients in the ramipril, telmisartan, and combination therapy groups, respectively). Baseline patient characteristics showed higher frequencies of coronary artery disease, Asian ethnicity, and use of statins and beta blockers than the main ONTARGET trial. LV mass decreased in all groups (p <0.0001 for each), but there were no significant differences in change in LV mass or volume among ...Continue Reading

References

Jan 1, 1989·International Journal of Cardiac Imaging·P R van DijkmanE E van der Wall
Apr 29, 1998·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·R E SchmiederP Martus
Jan 20, 2000·The New England Journal of Medicine·UNKNOWN Heart Outcomes Prevention Evaluation Study InvestigatorsG Dagenais
Mar 19, 2002·Hypertension·Saul G MyersonDudley J Pennell
May 9, 2002·Journal of Magnetic Resonance Imaging : JMRI·David S FienoJ Paul Finn
Jul 18, 2003·The American Journal of Medicine·Arnfried U KlingbeilRoland E Schmieder
Aug 28, 2004·Diabetes·Garth J S CooperJohn R Baker
May 4, 2005·Acta Diabetologica·P Sleight
Apr 2, 2008·The New England Journal of Medicine·UNKNOWN ONTARGET InvestigatorsCraig Anderson

❮ Previous
Next ❯

Citations

May 25, 2010·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·A DavenportUNKNOWN Acute Dialysis Quality Initiative (ADQI) consensus group
Feb 1, 2010·Therapeutic Advances in Endocrinology and Metabolism·Ghassan Jarred, R Lee Kennedy
Oct 4, 2013·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Ryota YoshitomiTakanari Kitazono
Feb 1, 2011·Revista española de cardiología·Alberto CorderoPilar Mazón
Jan 13, 2015·JACC. Cardiovascular Imaging·Brett R CowanAlistair A Young
Aug 28, 2014·Journal of Cardiovascular Magnetic Resonance : Official Journal of the Society for Cardiovascular Magnetic Resonance·Pau Medrano-GraciaAlistair A Young
Aug 30, 2011·The American Journal of Cardiology·Alberto CorderoVicente Bertomeu-Martínez
May 9, 2012·International Journal of Cardiology·Hannes ReuterErland Erdmann
Sep 15, 2016·The International Journal of Cardiovascular Imaging·Jonathan E N LangtonAlistair A Young
Jul 19, 2013·Circulation. Cardiovascular Imaging·Thomas H MarwickSteffen E Petersen
Dec 7, 2013·The Cochrane Database of Systematic Reviews·Deirdre A Lane, Gregory Y H Lip
Sep 14, 2012·Journal of Hypertension·Markus P Schneider, Roland E Schmieder
Jun 12, 2013·Expert Review of Cardiovascular Therapy·Giuseppe Derosa, Pamela Maffioli

❮ Previous
Next ❯

Related Concepts

Related Feeds

Atrial Filbrillation

Atrial fibrillation refers to the abnormal heart rhythm characterized by rapid and irregular beating of the atria. Here is the latest research.

Antianginal Drugs: Mechanisms of Action

Antianginal drugs, including nitrates, beta-blockers, and calcium channel blockers, are used in the treatment of angina pectoris. Here is the latest research on their use and their mechanism of action.

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

Anthelmintics

Anthelmintics or antihelminthics are a group of antiparasitic drugs that expel parasitic worms (helminths) and other internal parasites from the body by either stunning or killing them and without causing significant damage to the host. Discover the latest research on anthelmintics here.

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Atherosclerosis Disease Progression

Atherosclerosis is the buildup of plaque on artery walls, causing stenosis which can eventually lead to clinically apparent cardiovascular disease. Find the latest research on atherosclerosis disease progression here.

Cardiovascular Diseases: Risk Factors

Cardiovascular disease is a significant health concern. Risk factors include hypertension, obesity, dyslipidemia and smoking. Women who are postmenopausal are at an increased risk of heart disease. Here is the latest research for risk factors of cardiovascular disease.